B2

B2 is a specific sublingual tablet formulation of plant-derived cannabis extract developed by Breath of Life International Pharma Ltd (BOL Pharma). It contains a fixed-dose combination of 30 mg cannabidiol (CBD) and 5 mg delta-9-tetrahydrocannabinol (THC). The drug is designed for sublingual administration to improve bioavailability and provide a controlled delivery of cannabinoids by bypassing first-pass metabolism. It has been evaluated in Phase 1 clinical trials for safety and pharmacokinetics, with intended therapeutic applications in treating autism spectrum disorder (ASD) and neuropathic pain. Its mechanism of action involves the modulation of the endocannabinoid system, primarily through the interaction of THC with CB1 and CB2 receptors and CBD's multi-target activity, including its effects on 5-HT1A receptors and its role as a negative allosteric modulator of CB1.

Other names

Sublingual cannabis tablet (30mg CBD/5mg THC)